Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BC2059 + Bortezomib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BC2059||CTNNB1 Inhibitor 26||BC2059 binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235).|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||BC2059 + Bortezomib||Preclinical - Patient cell culture||Actionable||In a preclinical study, the combination of BC2059 and Velcade (bortezomib) worked additively or synergistically in several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture (PMID: 28500235).||28500235|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|